AOMS1
MCID: ABD017
MIFTS: 48

Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2 (AOMS1)

Categories: Genetic diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2

MalaCards integrated aliases for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2:

Name: Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2 58
Abdominal Obesity-Metabolic Syndrome 58 12 13 15
Abdominal Obesity Metabolic Syndrome 54 74
Metabolic Syndrome X 54 74
Aoms1 54
Aoms2 58

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant


HPO:

33
abdominal obesity-metabolic syndrome quantitative trait locus 2:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:0060611
OMIM 58 605572
MedGen 43 C1854170

Summaries for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2

MalaCards based summary : Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2, also known as abdominal obesity-metabolic syndrome, is related to abdominal obesity-metabolic syndrome 1 and diabetes mellitus, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2 is AOMS1 (Abdominal Obesity-Metabolic Syndrome QTL1), and among its related pathways/superpathways are Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) and AMP-activated Protein Kinase (AMPK) Signaling. The drugs Cilostazol and Olanzapine have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and endothelial, and related phenotypes are hypertension and abdominal obesity

Description from OMIM: 605572

Related Diseases for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2

Diseases related to Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Related Disease Score Top Affiliating Genes
1 abdominal obesity-metabolic syndrome 1 31.7 AOMS1 HSD11B1 INS LEP SLC2A4
2 diabetes mellitus 28.9 CRP INS LEP SLC2A4
3 diabetes mellitus, noninsulin-dependent 28.5 CRP HSD11B1 INS LEP PPARD SLC2A4
4 abdominal obesity-metabolic syndrome 3 12.8
5 lipodystrophy, familial partial, type 1 10.2 INS LEP
6 complete generalized lipodystrophy 10.2 INS LEP
7 lipodystrophy, congenital generalized, type 1 10.2 INS LEP
8 lipodystrophy, familial partial, type 2 10.2 INS LEP
9 nonalcoholic steatohepatitis 10.2 INS LEP
10 fatty liver disease, nonalcoholic 1 10.2 INS LEP
11 fetal macrosomia 10.2 INS LEP
12 familial partial lipodystrophy 10.1 INS LEP
13 alstrom syndrome 10.1 INS LEP
14 acquired generalized lipodystrophy 10.1 INS LEP
15 acanthosis nigricans 10.1 INS LEP
16 pituitary-dependent cushing's disease 10.1 HSD11B1 INS
17 3-hydroxyacyl-coa dehydrogenase deficiency 10.0 INS LEP
18 malignant otitis externa 10.0 CRP INS
19 diabetic neuropathy 10.0 INS LEP
20 hyperandrogenism 9.9 HSD11B1 INS
21 acute insulin response 9.9 CRP INS
22 endocrine pancreas disease 9.9 INS LEP SLC2A4
23 gestational diabetes 9.8 INS LEP SLC2A4
24 prediabetes syndrome 9.8 CRP INS LEP
25 apnea, obstructive sleep 9.8 CRP INS LEP
26 pancreas disease 9.8 CRP INS LEP
27 sleep disorder 9.8 CRP INS LEP
28 anovulation 9.8 CRP INS LEP
29 inherited metabolic disorder 9.8 CRP INS LEP
30 sleep apnea 9.8 CRP INS LEP
31 uremia 9.7 CRP INS LEP
32 arteries, anomalies of 9.7 CRP INS LEP
33 lipid metabolism disorder 9.7 CRP INS LEP
34 morbid obesity 9.7 CRP INS LEP
35 maturity-onset diabetes of the young, type 1 9.7 CRP INS LEP
36 chronic kidney failure 9.7 CRP INS LEP
37 coronary heart disease 1 9.7
38 myocardial infarction 9.7
39 acute myocardial infarction 9.7
40 heart disease 9.7
41 conn's syndrome 9.7
42 central retinal artery occlusion 9.7
43 vascular disease 9.7
44 hyperglycemia 9.7
45 retinal artery occlusion 9.7
46 nutritional deficiency disease 9.6 CRP LEP
47 glucose metabolism disease 9.4 CRP INS LEP SLC2A4
48 acquired metabolic disease 9.4 CRP INS LEP SLC2A4
49 glucose intolerance 9.4 CRP INS LEP SLC2A4
50 overnutrition 9.1 CRP HSD11B1 INS LEP SLC2A4

Graphical network of the top 20 diseases related to Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2:



Diseases related to Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2

Symptoms & Phenotypes for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2

Human phenotypes related to Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2:

33
# Description HPO Frequency HPO Source Accession
1 hypertension 33 HP:0000822
2 abdominal obesity 33 HP:0012743

Symptoms via clinical synopsis from OMIM:

58
Cardiovascular Vascular:
hypertension

Laboratory Abnormalities:
elevated fasting glucose levels

Growth Weight:
abdominal obesity

Clinical features from OMIM:

605572

UMLS symptoms related to Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2:


angina pectoris, edema, chest pain

MGI Mouse Phenotypes related to Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 adipose tissue MP:0005375 9.88 DBI HSD11B1 INS LEP PPARD SLC2A4
2 growth/size/body region MP:0005378 9.87 DBI HSD11B1 INS LEP PPARD SLC27A4
3 homeostasis/metabolism MP:0005376 9.86 CRP DBI HSD11B1 INS LEP PPARD
4 digestive/alimentary MP:0005381 9.77 INS LEP PPARD SLC27A4 SLC2A4
5 integument MP:0010771 9.63 DBI HSD11B1 INS LEP PPARD SLC27A4
6 liver/biliary system MP:0005370 9.43 DBI HSD11B1 INS LEP PPARD SLC2A4
7 muscle MP:0005369 9.02 HSD11B1 INS LEP PPARD SLC2A4

Drugs & Therapeutics for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2

Drugs for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 240)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
2
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
3
Galantamine Approved Phase 4 357-70-0 9651
4
Zinc Approved, Investigational Phase 4,Phase 2 7440-66-6 32051
5
Ramipril Approved Phase 4 87333-19-5 5362129
6
Eplerenone Approved Phase 4 107724-20-9 150310 443872
7
Atorvastatin Approved Phase 4,Phase 2 134523-00-5 60823
8
Clopidogrel Approved Phase 4,Not Applicable 120202-66-6, 113665-84-2 60606
9
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
10
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
11
Polyestradiol phosphate Approved Phase 4 28014-46-2
12
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
13
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
14
Fenofibrate Approved Phase 4,Phase 2,Not Applicable 49562-28-9 3339
15
Rosiglitazone Approved, Investigational Phase 4,Phase 1,Phase 2 122320-73-4 77999
16
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
17
Nifedipine Approved Phase 4 21829-25-4 4485
18
Amlodipine Approved Phase 4 88150-42-9 2162
19
Telmisartan Approved, Investigational Phase 4,Phase 3 144701-48-4 65999
20
Angiotensin II Approved, Investigational Phase 4,Phase 3 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
21
Nitric Oxide Approved Phase 4 10102-43-9 145068
22
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
23
Dopamine Approved Phase 4,Not Applicable 62-31-7, 51-61-6 681
24
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
25
Ziprasidone Approved Phase 4 146939-27-7 60854
26
Aripiprazole Approved, Investigational Phase 4,Not Applicable 129722-12-9 60795
27
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
28
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
29
Serine Approved, Nutraceutical Phase 4 56-45-1 5951
30
Calcium Approved, Nutraceutical Phase 4,Not Applicable 7440-70-2 271
31
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 59-30-3 6037
32
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
33
Cilnidipine Investigational Phase 4 132203-70-4 5282138
34 Vasodilator Agents Phase 4,Not Applicable
35 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Not Applicable
36 Fibrinolytic Agents Phase 4,Not Applicable
37 Anti-Asthmatic Agents Phase 4
38 Autonomic Agents Phase 4,Not Applicable
39 Bronchodilator Agents Phase 4
40 Phosphodiesterase 3 Inhibitors Phase 4
41 Respiratory System Agents Phase 4,Not Applicable
42 Neuroprotective Agents Phase 4,Not Applicable
43 Platelet Aggregation Inhibitors Phase 4,Phase 2,Not Applicable
44 Phosphodiesterase Inhibitors Phase 4
45 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Neurotransmitter Agents Phase 4,Phase 3,Not Applicable
47 Hypoglycemic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 insulin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Contraceptive Agents Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 194)
# Name Status NCT ID Phase Drugs
1 Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness Unknown status NCT00573950 Phase 4 cilostazol;Placebo
2 Galantamine Effects in Patients With Metabolic Syndrome Completed NCT02283242 Phase 4 Galantamine;Placebo (for galantamine)
3 Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion Completed NCT02113241 Phase 4 Dapagliflozin;Placebo
4 Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity Terminated NCT00608465 Phase 4 Eplerenone;Ramipril
5 Diurnal Variation of Plasminogen Activator Inhibitor-1 Completed NCT00515021 Phase 4 Eplerenone (Morning);Eplerenone (Night-time)
6 ROMEO (Rosuvastatin in Metabolic syndrOme) Completed NCT00395486 Phase 4 Rosuvastatin;Atorvastatin
7 PROCLAIM: Study Examining Effects of Clopidogrel Compared to Placebo on Inflammation in Subjects With Metabolic Syndrome Completed NCT00296803 Phase 4 clopidogrel
8 Oral Contraceptives in the Metabolic Syndrome Completed NCT00205504 Phase 4 Ortho Tri Cyclen
9 Aldosterone Antagonism and Microvascular Function Terminated NCT01887119 Phase 4 Eplerenone
10 Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia Completed NCT00304993 Phase 4 fenofibrate;niacin;rosiglitazone
11 The Effects of Cilnidipine on Metabolic Syndrome Improvement Completed NCT00325936 Phase 4 Cilnidipine
12 Phase IV, 9 Weeks Comparison Between MICARDIS 80 mg and Amlodipine 10 mg on Biological PPAR Gamma Activities Completed NCT00242814 Phase 4 Micardis;Amlodipine
13 Rosiglitazone Versus Placebo in Chronic Stable Angina Terminated NCT00225355 Phase 4 Rosiglitazone
14 Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome Completed NCT00272311 Phase 4 Aspirin
15 Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes Completed NCT00338949 Phase 4 Ziprasidone;Standard atypical antipsychotic drug
16 The Effects of Aripiprazole on Patients With Metabolic Syndrome Completed NCT00224822 Phase 4 Aripiprazole
17 Treatment of Adiposity Related hypErTension (TARGET) Completed NCT01138423 Phase 4 Aliskiren;Moxonidine;Hydrochlorothiazide;Placebo (for aliskiren);Placebo (for moxonidine and hydrochlorothiazide)
18 Study of Growth-promoting and Metabolic Effects of Growth Hormone (rhGH) Terminated NCT00597480 Phase 4 rhGH (Norditropine SimpleXx®);rhGH norditropine simple Xx
19 Effect of a Meal Replacement on Weight Loss Obesity Patients With Metabolic Syndrome Unknown status NCT02626741 Phase 3
20 Therapeutic Efficacy of Phytosterols on Metabolic Syndrome Unknown status NCT02969720 Phase 3
21 Evaluation of Effect of Exercise on Prescription Unknown status NCT00399997 Phase 2, Phase 3
22 Efficacy and Safety Study of ALS-L1023 in Patients With Abdominal Obesity of Metabolic Syndrome Terminated NCT01872182 Phase 3 ALS-L1023;placebo
23 The Improvements of Dietary Supplement of Black Rice on Metabolic Syndrome Completed NCT02407522 Phase 2, Phase 3
24 Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study Completed NCT01849068 Phase 3 Ezetimibe;Placebo
25 Brown Rice Intervention on Metabolic Syndrome (BRIMS) Completed NCT01022411 Phase 2, Phase 3
26 Walnut Intervention on Metabolic Syndrome (WIMS) Completed NCT00742742 Phase 2, Phase 3
27 Flaxseed Intervention on Metabolic Syndrome Completed NCT00733772 Phase 2, Phase 3
28 Telmisartan-Induced Reduction in Intra-Myocellular Lipids Trial Completed NCT00147264 Phase 3 Telmisartan (Micardis®) vs. Placebo
29 Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome Completed NCT00111956 Phase 2, Phase 3 Etanercept;Placebo
30 Dietetic and Hygiene Measures in Metabolic Neuropathies: the Neurodiet Study Completed NCT01465620 Phase 3
31 Effects of Interleukin-1 Beta on Low Testosterone Levels in Men With Obesity and Metabolic Syndrome Completed NCT02672592 Phase 3 Anakinra;Sodium Chloride 0.9%
32 Efficacy of Topiramate for Weight Loss in Subjects With Metabolic Syndrome Suspended NCT00243984 Phase 3 topiramate
33 Effects of NUTRIOSE®FB Dietary Fiber Supplementation on Satiety, Body Fat, and Metabolic Syndrome in Overweight Adult Men Completed NCT01044680 Phase 2, Phase 3
34 Surgical Removal of Visceral Fat Tissue (Omentectomy) Associated to Bariatric Surgery: Effects on Insulin Sensitivity Completed NCT00545805 Phase 2, Phase 3
35 Berberine as Adjuvant Treatment for Schizophrenia Patients Recruiting NCT02983188 Phase 2, Phase 3 Berberine;Placebos;Antipsychotic Agents
36 Effect of Exercise and Phytoestrogen on Bone, Metabolic Syndrome Criteria and Complaints of the Early Menopause Terminated NCT00663104 Phase 3
37 Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue Completed NCT01794429 Phase 3 Exenatide;Placebo
38 Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant Terminated NCT00228176 Phase 3 Rimonabant;Placebo (for Rimonabant)
39 Evaluation of the Effects of a L.Reuteri Strain on Markers of Inflammation, Cardiovascular Risk and Fatty Liver Disease Unknown status NCT02972567 Phase 2
40 Probiotic Bacteria in Prevention of the Metabolic Syndrome Completed NCT02288572 Phase 2
41 Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome Completed NCT00671515 Phase 2 Pioglitazone
42 Effect of Banaba (Lagerstroemia Speciosa) on Metabolic Syndrome, Insulin Secretion and Insulin Sensitivity Completed NCT02767869 Phase 2 Banaba;placebo
43 Effect of Irvingia Gabonensis Administration on Metabolic Syndrome, Insulin Secretion and Insulin Sensitivity Completed NCT02354339 Phase 2
44 Effect of Ursolic Acid Administration on Insulin Sensitivity and Metabolic Syndrome Completed NCT02337933 Phase 2 Ursolic acid;Placebo
45 Effect of Resveratrol Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion Completed NCT02114892 Phase 2 Resveratrol;Placebo
46 Efficacy of a Prebiotic Galactooligosaccharide to Reduce Metabolic Syndrome Risk Factors in Overweight Adults Completed NCT01004120 Phase 1, Phase 2
47 The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study Completed NCT00400231 Phase 2 Study drugs: Metformin and fenofibrate;Study Drug: Metformin;Study Drug: fenofibrate;Metformin and Fenofibrate placebo
48 A Mechanistic Study of the Effects of LY518674 on High-Density Lipoprotein Cholesterol (HDL-C) Metabolism Completed NCT00327002 Phase 2 LY518674
49 Study In Patients With Dyslipidaemia Completed NCT00264667 Phase 2 GW677954
50 Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity Suspended NCT01351753 Phase 2 Metformin;Orlistat;Topiramate;Placebo

Search NIH Clinical Center for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2

Genetic Tests for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2

Anatomical Context for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2

MalaCards organs/tissues related to Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2:

42
Liver, Heart, Endothelial, Brain, Bone, Ovary, Skeletal Muscle

Publications for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2

Articles related to Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2:

# Title Authors Year
1
Abdominal obesity, metabolic syndrome in type 1 diabetic children and adolescents. ( 20455417 )
2009
2
The link between abdominal obesity, metabolic syndrome and cardiovascular disease. ( 17110092 )
2007
3
Association of hypertension with single nucleotide polymorphisms in the quantitative trait locus for abdominal obesity-metabolic syndrome on chromosome 17. ( 16511504 )
2006

Variations for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2

Expression for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2

Search GEO for disease gene expression data for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2.

Pathways for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2

GO Terms for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2

Biological processes related to Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2 according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 lipid metabolic process GO:0006629 9.8 HSD11B1 LEP PPARD SLC27A4
2 fatty acid beta-oxidation GO:0006635 9.57 LEP PPARD
3 response to activity GO:0014823 9.56 LEP PPARD
4 placenta development GO:0001890 9.55 LEP PPARD
5 acute-phase response GO:0006953 9.54 CRP INS
6 adipose tissue development GO:0060612 9.52 LEP PPARD
7 positive regulation of blood vessel diameter GO:0097755 9.51 INS PPARD
8 glucose homeostasis GO:0042593 9.5 INS LEP SLC2A4
9 glucose transmembrane transport GO:1904659 9.48 PPARD SLC2A4
10 positive regulation of insulin receptor signaling pathway GO:0046628 9.46 INS LEP
11 regulation of fat cell differentiation GO:0045598 9.43 LEP PPARD
12 fatty acid catabolic process GO:0009062 9.4 LEP PPARD
13 fatty acid transport GO:0015908 9.37 PPARD SLC27A4
14 negative regulation of blood vessel diameter GO:0097756 9.26 CRP INS
15 negative regulation of lipid storage GO:0010888 9.16 CRP LEP
16 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.13 INS LEP PPARD
17 glucose metabolic process GO:0006006 8.8 INS LEP PPARD

Sources for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....